Last reviewed · How we verify

cisplatin and fluorouracil

Sun Yat-sen University · Phase 3 active Small molecule

cisplatin and fluorouracil is a Chemotherapy combination (platinum agent + antimetabolite) Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Advanced or metastatic cancers (specific indication under investigation in phase 3 trial not specified). Also known as: cisplatin and fluorouracil (PF).

Cisplatin and fluorouracil work together as a chemotherapy combination to damage cancer cell DNA and inhibit nucleotide synthesis, preventing tumor growth and proliferation.

Cisplatin and fluorouracil work together as a chemotherapy combination to damage cancer cell DNA and inhibit nucleotide synthesis, preventing tumor growth and proliferation. Used for Advanced or metastatic cancers (specific indication under investigation in phase 3 trial not specified).

At a glance

Generic namecisplatin and fluorouracil
Also known ascisplatin and fluorouracil (PF)
SponsorSun Yat-sen University
Drug classChemotherapy combination (platinum agent + antimetabolite)
TargetDNA (cisplatin); thymidylate synthase and nucleotide metabolism (fluorouracil)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Cisplatin is a platinum-based alkylating agent that forms DNA cross-links, causing irreversible damage to cancer cells. Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about cisplatin and fluorouracil

What is cisplatin and fluorouracil?

cisplatin and fluorouracil is a Chemotherapy combination (platinum agent + antimetabolite) drug developed by Sun Yat-sen University, indicated for Advanced or metastatic cancers (specific indication under investigation in phase 3 trial not specified).

How does cisplatin and fluorouracil work?

Cisplatin and fluorouracil work together as a chemotherapy combination to damage cancer cell DNA and inhibit nucleotide synthesis, preventing tumor growth and proliferation.

What is cisplatin and fluorouracil used for?

cisplatin and fluorouracil is indicated for Advanced or metastatic cancers (specific indication under investigation in phase 3 trial not specified).

Who makes cisplatin and fluorouracil?

cisplatin and fluorouracil is developed by Sun Yat-sen University (see full Sun Yat-sen University pipeline at /company/sun-yat-sen-university).

Is cisplatin and fluorouracil also known as anything else?

cisplatin and fluorouracil is also known as cisplatin and fluorouracil (PF).

What drug class is cisplatin and fluorouracil in?

cisplatin and fluorouracil belongs to the Chemotherapy combination (platinum agent + antimetabolite) class. See all Chemotherapy combination (platinum agent + antimetabolite) drugs at /class/chemotherapy-combination-platinum-agent-antimetabolite.

What development phase is cisplatin and fluorouracil in?

cisplatin and fluorouracil is in Phase 3.

What are the side effects of cisplatin and fluorouracil?

Common side effects of cisplatin and fluorouracil include Nausea and vomiting, Myelosuppression (neutropenia, thrombocytopenia), Nephrotoxicity, Ototoxicity, Peripheral neuropathy, Mucositis.

What does cisplatin and fluorouracil target?

cisplatin and fluorouracil targets DNA (cisplatin); thymidylate synthase and nucleotide metabolism (fluorouracil) and is a Chemotherapy combination (platinum agent + antimetabolite).

Related